{"id":"NCT00997035","sponsor":"University of California, San Francisco","briefTitle":"The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo","officialTitle":"The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-05","primaryCompletion":"2016-01","completion":"2016-03","firstPosted":"2009-10-16","resultsPosted":"2017-06-14","lastUpdate":"2019-02-26"},"enrollment":240,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Corneal Ulcer","Eye Infections, Fungal"],"interventions":[{"type":"DRUG","name":"Voriconazole","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Oral Voriconazole","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if the addition of oral voriconazole to topical treatment regimens results in lower rates of perforation in severe fungal corneal ulcers.","primaryOutcome":{"measure":"Incidence of Perforation or Therapeutic Penetrating Keratoplasty","timeFrame":"3 months from enrollment","effectByArm":[{"arm":"Oral Voriconazole","deltaMin":0.0095562,"sd":null},{"arm":"Oral Placebo","deltaMin":0.011204,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.29"}]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":15},"locations":{"siteCount":7,"countries":["United States","India","Nepal"]},"refs":{"pmids":["40372030"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":121},"commonTop":["Headache","Increase in hypopyon (increase>2mm)","AST or ALT elevated to twice upper limit of normal","Ulcer not healing after 6 weeks of therapy","Dizziness"]}}